Abstract:Aim. Cancer patients with reduced dihydropyrimidine dehydrogenase (DPD)
activity are at increased risk of severe fluoropyrimidine (FP)-related
adverse events (AE). Guidelines recommend FP dosing adjusted to
genotype-predicted DPD activity based on four DPYD variants
(rs3918290, rs55886062, rs67376798, rs56038477). We evaluated
relationship between three further DPYD polymorphisms
[c.496A>G (rs2297595), *6
c.2194G>A (rs1801160) and *9A c.85T>C
(rs1801265)] and the risk of severe AEs. Methods. Consecuti… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.